305 related articles for article (PubMed ID: 10507743)
1. Raloxifene: a selective estrogen receptor modulator.
Scott JA; Da Camara CC; Early JE
Am Fam Physician; 1999 Sep; 60(4):1131-9. PubMed ID: 10507743
[TBL] [Abstract][Full Text] [Related]
2. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women.
Draper MW; Flowers DE; Huster WJ; Neild JA; Harper KD; Arnaud C
J Bone Miner Res; 1996 Jun; 11(6):835-42. PubMed ID: 8725181
[TBL] [Abstract][Full Text] [Related]
3. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
[TBL] [Abstract][Full Text] [Related]
4. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.
Delmas PD; Bjarnason NH; Mitlak BH; Ravoux AC; Shah AS; Huster WJ; Draper M; Christiansen C
N Engl J Med; 1997 Dec; 337(23):1641-7. PubMed ID: 9385122
[TBL] [Abstract][Full Text] [Related]
5. [Raloxifene: a selective modulator of estrogen receptors].
van den Brûle FA; Kalbus MF; Gaspard UJ
J Gynecol Obstet Biol Reprod (Paris); 1999 Dec; 28(8):788-99. PubMed ID: 10635481
[TBL] [Abstract][Full Text] [Related]
6. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial.
Lufkin EG; Whitaker MD; Nickelsen T; Argueta R; Caplan RH; Knickerbocker RK; Riggs BL
J Bone Miner Res; 1998 Nov; 13(11):1747-54. PubMed ID: 9797484
[TBL] [Abstract][Full Text] [Related]
7. [Estrogen receptor and selective estrogen receptor modulators (SERMs)].
Shioi A; Nishizawa Y
Nihon Rinsho; 1999 May; 57(5):1199-207. PubMed ID: 10361456
[TBL] [Abstract][Full Text] [Related]
8. Clinical effects of raloxifene hydrochloride in women.
Khovidhunkit W; Shoback DM
Ann Intern Med; 1999 Mar; 130(5):431-9. PubMed ID: 10068418
[TBL] [Abstract][Full Text] [Related]
9. Raloxifene.
Balfour JA; Goa KL
Drugs Aging; 1998 Apr; 12(4):335-41; discussion 342. PubMed ID: 9571395
[TBL] [Abstract][Full Text] [Related]
10. [Selective estrogen receptor modulators (SERMs) in the practice].
Nagykálnai T
Magy Onkol; 2002; 46(2):165-75. PubMed ID: 12202896
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
Grese TA; Cho S; Finley DR; Godfrey AG; Jones CD; Lugar CW; Martin MJ; Matsumoto K; Pennington LD; Winter MA; Adrian MD; Cole HW; Magee DE; Phillips DL; Rowley ER; Short LL; Glasebrook AL; Bryant HU
J Med Chem; 1997 Jan; 40(2):146-67. PubMed ID: 9003514
[TBL] [Abstract][Full Text] [Related]
12. Is raloxifene the answer to the HRT story?
Apgar B
Am Fam Physician; 1999 Sep; 60(4):1092, 1095. PubMed ID: 10507739
[No Abstract] [Full Text] [Related]
13. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women.
Dias AR; Melo RN; Gebara OC; D'Amico EA; Nussbacher A; Halbe HW; Pinotti JA
Climacteric; 2005 Mar; 8(1):63-70. PubMed ID: 15804733
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy of SERMs.
Dere WH
Aging (Milano); 1998 Apr; 10(2):160-1. PubMed ID: 9666217
[No Abstract] [Full Text] [Related]
15. Raloxifene: bone and cardiovascular effects.
Francucci CM; Romagni P; Boscaro M
J Endocrinol Invest; 2005; 28(10 Suppl):85-9. PubMed ID: 16550730
[TBL] [Abstract][Full Text] [Related]
16. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
Shintani M
Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
[TBL] [Abstract][Full Text] [Related]
17. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harpe K
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):269-73. PubMed ID: 15059505
[TBL] [Abstract][Full Text] [Related]
18. Raloxifene: designer estrogen for preventing postmenopausal osteoporosis.
Park L; Evans MF
Can Fam Physician; 1999 May; 45():1191-3. PubMed ID: 10349062
[No Abstract] [Full Text] [Related]
19. Selective estrogen receptor modulators: a new category of compounds to extend postmenopausal women's health.
Goldstein SR
Int J Fertil Womens Med; 1999; 44(5):221-6. PubMed ID: 10569450
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
Grese TA; Pennington LD; Sluka JP; Adrian MD; Cole HW; Fuson TR; Magee DE; Phillips DL; Rowley ER; Shetler PK; Short LL; Venugopalan M; Yang NN; Sato M; Glasebrook AL; Bryant HU
J Med Chem; 1998 Apr; 41(8):1272-83. PubMed ID: 9548817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
